December 2005 in “Journal of Marine Fisheries” Telogen effluvium causes temporary hair loss, often triggered by stress or health issues, with hair usually regrowing over time.
December 2005 in “Journal of Marine Fisheries” Telogen effluvium causes temporary hair loss, often triggered by stress or health issues, with hair usually regrowing over time.
September 2011 in “Urology” Biofeedback treatment for dysfunctional voiding in adults showed no symptom improvement.
6 citations
,
July 2023 in “Spine Surgery and Related Research” PRP shows promise for spinal pain but needs more guidelines before widespread use.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
October 2021 in “Journal of Investigative Dermatology” Skin changes in Pseudoxanthoma elasticum patients can indicate the severity of related health issues.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
White phosphorus bombs cause severe physical and emotional harm.
Telogen Effluvium causes increased hair shedding and can be challenging to diagnose and treat.
February 1994 in “Archives of Dermatology” Telogen effluvium is a condition that causes temporary hair loss.
May 2025 in “The Journal of Rheumatology” Antiphospholipid syndrome can severely damage adrenal glands, requiring early diagnosis and treatment.
April 2022 in “Archives of Medical Case Reports and Case Study” COVID-19 pneumonia requires more intensive care, including monitoring liver functions and DVT, due to higher D-dimer and procalcitonin levels.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
April 2015 in “Journal of the American Academy of Dermatology” The woman likely has secondary syphilis, treatable with penicillin.
September 2024 in “World Journal of Advanced Research and Reviews” COVID-19 can harm many body parts, not just the lungs.
April 2024 in “Benha Medical Journal” H. pylori infection may be linked to the hair shedding condition Telogen Effluvium.
December 2024 in “Journal of Cosmetic Dermatology” Oral minoxidil rarely causes pericardial effusion, especially at low doses.
6 citations
,
September 2024 in “BMC Pulmonary Medicine” Cepharanthine may help treat lung fibrosis by affecting certain immune cells.
1 citations
,
February 1977 in “Archives of Dermatology” Fresh plasma transfusions did not help treat Leiner disease in an infant.
18 citations
,
October 2020 in “PLoS ONE” Caregiver burden and patient health issues significantly affect emotional distress in both COPD patients and their caregivers.
November 2024 in “Rheumatology Advances in Practice” Timely diagnosis of SLE is crucial due to symptom overlap with fibromyalgia.
May 2025 in “The Journal of Rheumatology” Early recognition and management of gastrointestinal tuberculosis in lupus patients are crucial to prevent complications.
November 2023 in “Journal of cosmetic dermatology” The 595-nm pulsed dye laser effectively reduces symptoms of EFFC with minimal side effects.
January 2023 in “Faculty of 1000 Research Ltd” People with weakened immune systems, like those with SLE, are at higher risk for TB.
8 citations
,
June 2024 in “Pharmaceutics” PEA-ENL improves skin delivery and reduces inflammation without side effects.
January 2018 in “Jaypee Brothers Medical Publishers (P) Ltd. eBooks” Telogen effluvium is a condition that causes temporary hair loss due to stress or shock to the body.
January 2014 in “Jaypee Brothers Medical Publishers (P) Ltd. eBooks” Telogen effluvium is a condition that causes temporary hair loss due to stress or shock to the body.
January 1998 in “Jaypee Brothers Medical Publishers (P) Ltd. eBooks” Telogen effluvium is a condition that causes temporary hair loss due to stress or shock to the body.
5 citations
,
August 1998 in “PubMed” Intravenous cyclophosphamide effectively treated steroid-resistant lupus cystitis and peritonitis.
9 citations
,
October 2015 in “Journal of Cutaneous Pathology” Erythematous papulopustular eruptions in cancer patients using EGFR inhibitors show specific skin changes that vary with severity and treatment type.